Cargando…
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–), PIK3CA-mutated, advanced breast cancer (ABC). Hyperglycemia is a common,...
Autores principales: | Blow, Tahj, Hyde, Parker N., Falcone, John N., Neinstein, Aaron, Vasan, Neil, Chitkara, Ritika, Hurd, Maurice A., Sardesai, Sagar, Lustberg, Maryam B., Flory, James H., Volek, Jeff S., Goncalves, Marcus D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283040/ https://www.ncbi.nlm.nih.gov/pubmed/34259084 http://dx.doi.org/10.1177/15347354211032283 |
Ejemplares similares
-
Alpelisib-Induced Hyperglycemia- A Small Case Series
por: Ekanayake, Preethika Subashini, et al.
Publicado: (2021) -
Genetic variants for personalised management of very low carbohydrate ketogenic diets
por: Aronica, Lucia, et al.
Publicado: (2020) -
Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib
por: Handy, Caitlin, et al.
Publicado: (2021) -
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023) -
ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)